Alto Neuroscience Q1 2024 Adj EPS $(0.76) Misses $(0.46) Estimate
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience reported Q1 2024 adjusted EPS losses of $(0.76), missing the consensus estimate of $(0.46) by 65.22%.
May 14, 2024 | 8:23 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Alto Neuroscience's Q1 2024 earnings report showed a significant miss against analyst expectations, with adjusted EPS losses of $(0.76) compared to the estimated $(0.46).
Earnings misses typically lead to negative investor sentiment in the short term, as they may indicate underlying issues not previously accounted for by the market. Given the significant miss of 65.22%, this is likely to put downward pressure on ANRO's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100